Cf-252 brain implantation for malignant glioma: Experience of the University of Kentucky, Lexington

Chin, H W; Maruyama, Y; Yong, A B; Beach, J L; Tibbs, P A; Markesbery, W

Title: Cf-252 brain implantation for malignant glioma: Experience of the University of Kentucky, Lexington

Full Record
Other Related Research

Abstract

Since 1980, --65 patients with hemispheric malignant gliomas have been treated in studies testing Cf-252 neutron brain implant therapy combined with whole/part brain radiotherapy to --6000 cGy. Methods, techniques, number of tubes implanted and the placement of tubes relative to the contrast enhanced edge of the tumor and brain imaging have evolved during this time. The patients receiving single tube implant had marked improvement in their performance status but a survival period of only --1 year. With the use of multiple tubes, survival results improved and was 63% at 12 months and continues at --30% at about 2 years. The advent of tumor staging using CT and MR scanning, multiple tube stereotaxic implants placed around the enhancing edge of the lesion and whole/part brain radiation may further improve local tumor control. Methods for the conduct of a therapeutic trial that could lead to more effective treatment of malignant tumors appear to be evolving.

Authors:: Chin, H W; Maruyama, Y; Yong, A B; Beach, J L; Tibbs, P A; Markesbery, W

Publication Date:: Wed Jan 01 00:00:00 EST 1986

Research Org.:: Radiation Therapy Oncology Center, Univ. of Kentucky Medical Center, Lexington, KY

OSTI Identifier:: 6718287

Resource Type:: Journal Article

Journal Name:: Nucl. Sci. Appl.; (United States)

Additional Journal Information:: Journal Volume: 2:3

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; BRAIN; GLIOMAS; CALIFORNIUM 252; THERAPEUTIC USES; NEUTRON THERAPY; COMPUTERIZED TOMOGRAPHY; IMAGE PROCESSING; KENTUCKY; MEDICAL ESTABLISHMENTS; PATIENTS; RADIATION SOURCE IMPLANTS; SURVIVAL TIME; TUBES; ACTINIDE ISOTOPES; ACTINIDE NUCLEI; ALPHA DECAY RADIOISOTOPES; BODY; CALIFORNIUM ISOTOPES; CENTRAL NERVOUS SYSTEM; DIAGNOSTIC TECHNIQUES; DISEASES; EVEN-EVEN NUCLEI; FEDERAL REGION IV; HEAVY NUCLEI; IMPLANTS; ISOTOPES; MEDICINE; NEOPLASMS; NERVOUS SYSTEM; NORTH AMERICA; NUCLEAR MEDICINE; NUCLEI; ORGANS; PROCESSING; RADIATION SOURCES; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; THERAPY; TOMOGRAPHY; USA; USES; YEARS LIVING RADIOISOTOPES; 550603* - Medicine- External Radiation in Therapy- (1980-); 550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)

Citation Formats


                    Chin, H W, Maruyama, Y, Yong, A B, Beach, J L, Tibbs, P A, and Markesbery, W. Cf-252 brain implantation for malignant glioma: Experience of the University of Kentucky, Lexington.  United States: N. p., 1986. 
        Web.

Copy to clipboard


                    Chin, H W, Maruyama, Y, Yong, A B, Beach, J L, Tibbs, P A, & Markesbery, W. Cf-252 brain implantation for malignant glioma: Experience of the University of Kentucky, Lexington.  United States.

Copy to clipboard


                    Chin, H W, Maruyama, Y, Yong, A B, Beach, J L, Tibbs, P A, and Markesbery, W. 1986.  
        "Cf-252 brain implantation for malignant glioma: Experience of the University of Kentucky, Lexington".  United States.

Copy to clipboard


                    
@article{osti_6718287,

  title        = {Cf-252 brain implantation for malignant glioma: Experience of the University of Kentucky, Lexington},

  author       = {Chin, H W and Maruyama, Y and Yong, A B and Beach, J L and Tibbs, P A and Markesbery, W},

  abstractNote = {Since 1980, --65 patients with hemispheric malignant gliomas have been treated in studies testing Cf-252 neutron brain implant therapy combined with whole/part brain radiotherapy to --6000 cGy. Methods, techniques, number of tubes implanted and the placement of tubes relative to the contrast enhanced edge of the tumor and brain imaging have evolved during this time. The patients receiving single tube implant had marked improvement in their performance status but a survival period of only --1 year. With the use of multiple tubes, survival results improved and was 63% at 12 months and continues at --30% at about 2 years. The advent of tumor staging using CT and MR scanning, multiple tube stereotaxic implants placed around the enhancing edge of the lesion and whole/part brain radiation may further improve local tumor control. Methods for the conduct of a therapeutic trial that could lead to more effective treatment of malignant tumors appear to be evolving.},

  doi          = {},

  url          = {https://www.osti.gov/biblio/6718287},
  journal      = {Nucl. Sci. Appl.; (United States)},
number       = ,

  volume       = 2:3,

  place        = {United States},

  year         = {Wed Jan 01 00:00:00 EST 1986},

  month        = {Wed Jan 01 00:00:00 EST 1986}

}

Copy to clipboard

Journal Article:

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Neutron interstitial brachytherapy for malignant gliomas: a pilot study

Journal Article Patchell, R; Maruyama, Y; Tibbs, P; ... - J. Neurosurg.; (United States)

Fifty-six patients with malignant glioma were treated with implantation of the neutron-emitting element californium-252 (/sup 252/Cf) within 2 weeks after surgical debulking of the tumor. Implantation was performed using computerized tomography-guided placement of afterloading catheters, and the /sup 252/Cf sources were removed after approximately 300 neutron rads were delivered. Patients then received 6000 to 7000 conventional photon rads by external beam. The total photon-equivalent dose to the tumor ranged from 8100 to 9100 rads. The median survival time was 10 months, with 18-and 24-month survival rates of 28% and 19%, respectively. The results of reoperation or autopsy showed that patientsmore »« less
https://doi.org/10.3171/jns.1988.68.1.0067
Work in progress: /sup 252/Cf neutron brachytherapy for hemispheric malignant glioma

Journal Article Maruyama, Y; Chin, H; Young, A; ... - Radiology; (United States)

It has been shown that /sup 252/Cf neutron brachytherapy of hemispheric malignant glioma can be readily carried out and may be combined with external, whole brain photon beam therapy of 6,000 rad (60 Gy) administered over a five-week to seven-week period. The ten patients who were studied tolerated both procedures well. There was improvement in performance status, and a decrease in tumor size was observed upon computed tomographic scanning.
Work in progress: /sup 252/Cf neutron brachytherapy for hemispheric malignant glioma. [/sup 60/Co]

Journal Article Maruyama, Y; Chin, H; Young, A; ... - Radiology; (United States)

It has been shown that /sup 252/Cf neutron brachytherapy of hemispheric malignant glioma can be readily carried out and may be combined with external, whole brain photon beam therapy of 6,000 rad (60 Gy) administered over a five-week to seven-week period. The ten patients who were studied tolerated both procedures well. There was improvement in performance status, and a decrease in tumor size was observed upon computed tomographic scanning.
A malignant glioma therapeutic staging system for Cf-252 neutron brachytherapy at the University of Kentucky

Journal Article Maruyama, Y; Young, A; Chin, H; ... - Nucl. Sci. Appl.; (United States)

Cf-252 is a novel transplutonium radioactive isotope which emits fast neutrons and is useful for human malignant glioma implant therapy. A proposed therapeutic staging system is described using MRI and CT imaging to select patients for treatment using Cf-252 for malignant astrocytomas and glioblastoma multiforme.
Randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study

Conference Nelson, D; Schoenfeld, D; Weinstein, A; ... - Int. J. Radiat. Oncol., Biol. Phys.; (United States)

A randomized prospective was performed to evaluate misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. The control arm, Group A, consisted of conventional radiation therapy (6000 cGy/6 to 7 weeks) to the whole brain plus BCNU (80 mg/m/sup 3/ on day 3, 4, 5, and then repeated q 8 weeks for 2 years). The BCNU schedule was identical in both arms. In the experimental arm, Group B, misonidazole 2.5 gm/m/sup 2/ was given once a week for six weeks, to a total dose of 15 gm/m/sup 2/. It was given orally four hours prior to 400 cGy onmore »« less

Similar Records